Clinical Trial Update: A Phase I Study to Evaluate BFPET as a Potential Myocardial Perfusion Imaging(MPI) Agent for PET [Phase 1]

View source ↗

Summary

Phase I study assessing BFPET as a potential PET myocardial perfusion imaging agent for coronary artery disease. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• BFPET

Snippet

Sponsor: Fluoropharma, Inc. | Conditions: Coronary Artery Disease | Phase 1 | Status: COMPLETED